Latest Oncology News

IMpower010 Data Show OS Trend in Favor of Adjuvant Atezolizumab Vs BSC in PD-L1+ Resected NSCLC

IMpower010 Data Show OS Trend in Favor of Adjuvant Atezolizumab Vs BSC in PD-L1+ Resected NSCLC

August 8th 2022

Hayley Virgil

An overall survival trend in favor of adjuvant atezolizumab over best supportive care was observed in patients with stage II to IIIA resected non–small cell lung cancer with a PD-L1 tumor cell (TC) expression of at least 1%, with a clinically meaningful OS trend noted in those with a PD-L1 TC expression of 50% or higher.

Neoadjuvant Nivolumab Plus Chemo Improves Survival Vs Chemo Alone in Resectable Stage IIIA/B NSCLC

Neoadjuvant Nivolumab Plus Chemo Improves Survival Vs Chemo Alone in Resectable Stage IIIA/B NSCLC

August 8th 2022

Hayley Virgil

The addition of nivolumab to chemotherapy provided progression-free survival and overall survival benefits compared with chemotherapy alone in patients with stage IIIA/B non–small cell lung cancer.

Pembrolizumab Plus Lenvatinib Elicits Positive Clinical Activity in Recurrent Pleural Mesothelioma

Pembrolizumab Plus Lenvatinib Elicits Positive Clinical Activity in Recurrent Pleural Mesothelioma

August 7th 2022

Jordyn Sava

The combination of pembrolizumab and lenvatinib generated promising clinical activity with a manageable safety profile in pretreated patients with malignant pleural mesothelioma.

Sotorasib Plus SHP2 Inhibition Elicits Promising Preliminary Activity in KRAS G12C–Mutated NSCLC

Sotorasib Plus SHP2 Inhibition Elicits Promising Preliminary Activity in KRAS G12C–Mutated NSCLC

August 7th 2022

Caroline Seymour

The combination of sotorasib and the small molecule SHP2 inhibitor RMC-4630 led to an investigator-assessed objective response rate of 27% and 50% in pretreated and KRAS G12C inhibitor–naïve patients with non–small cell lung cancer, respectively.

VISION Trial Cohort C Data Confirm Robust Efficacy of Tepotinib in METex14-Altered NSCLC

VISION Trial Cohort C Data Confirm Robust Efficacy of Tepotinib in METex14-Altered NSCLC

August 7th 2022

Kristi Rosa

The robust efficacy achieved with tepotinib in patients with non–small cell lung cancer harboring MET exon 14 skipping alterations was independently confirmed in data from the primary analysis of cohort C of the phase 2 VISION trial.

Latest Oncology Videos

All Oncology News

Dr. Barba on the Safety of Obecabtagene Autoleucel in Relapsed/Refractory B-ALL

July 21st 2022

Pere Barba, MD, PhD

Pere Barba, MD, PhD, discusses the safety of obecabtagene autoleucel in patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

Brentuximab Vedotin Boosts Survival in Adult and AYA Patients with Advanced Hodgkin Lymphoma

July 20th 2022

OncLive Staff

Ann S. LaCasce, MD, MMSC, explains how bretuximab vedotin has produced a survival benefit in patients with advanced classic Hodgkin lymphoma.

Dr. Phillips on p53 Mutations in MCL

July 20th 2022

Tycel Jovelle Phillips, MD

Tycel Jovelle Phillips, MD, discusses the role of p53 mutations in the outcomes of patients with mantle cell lymphoma.

Dr. Kallam on the Role of BTK and PI3K Inhibitors in CNS Lymphoma

July 20th 2022

Avyakta Kallam, MBBS

Avyakta Kallam, MBBS, discusses the role of BTK and PI3K inhibitors in the treatment of patients with central nervous system lymphoma.

Dr. Mehta-Shah on the Variations of the CHOP Regimen in PTCL

July 20th 2022

Neha Mehta-Shah, MD

Neha Mehta-Shah, MD, MSCI, discusses variations of CHOP-based chemotherapy in peripheral T-cell lymphoma.

Mosunetuzumab Monotherapy Generates Promising Responses in Relapsed/Refractory Follicular Lymphoma

July 20th 2022

OncLive Staff

Single-agent mosunetuzumab produced a complete response rate that was greater than what has been observed with historical controls in patients with relapsed/refractory follicular lymphoma who had received at least 2 prior lines of therapy, meeting the primary end point of the expansion portion of the phase 1/2 GO29781 trial.

Dr. Kahl on the Evolving Standard of Care in MCL

July 20th 2022

Brad S. Kahl, MD

Brad S. Kahl, MD, discusses current best practices for the treatment of older patients with mantle cell lymphoma, as well as where the treatment paradigm might lead in the future.

Pembrolizumab Plus Chemoradiation Misses EFS End Point in Head and Neck Squamous Cell Carcinoma

July 20th 2022

Caroline Seymour

Pembrolizumab plus concurrent chemoradiation followed by pembrolizumab maintenance did not lead to a statistically significant improvement in event-free survival vs concurrent chemoradiation alone in patients with unresected locally advanced head and neck squamous cell carcinoma.

Rituximab Maintenance Therapy Continues to Provide Remission Benefit in MCL

July 20th 2022

Ashling Wahner

Brad S. Kahl, MD, explains the evolution of mantle cell lymphoma treatment over the past decade and lays out the trajectory for future therapies, including the potential benefits of lenalidomide in the maintenance setting.

Zanubrutinib Showcases Superior PFS Benefit Over BR in Treatment-Naïve CLL/SLL, Including High-Risk Subsets

July 20th 2022

OncLive Staff

Zanubrutinib was found to significantly improve progression-free survival over a doublet comprised of bendamustine plus rituximab in patients with treatment-naïve chronic lymphocytic leukemia and small lymphocytic lymphoma, according to data from cohort 1 of the phase 3 SEQUOIA trial.

Ofranergene Obadenovec/Paclitaxel Combo Misses Survival End Points in Platinum-Resistant Ovarian Cancer

July 20th 2022

Caroline Seymour

The combination of ofranergene obadenovec and paclitaxel failed to elicit a statistically significant improvement in progression-free survival or overall survival compared with paclitaxel alone in patients with platinum-resistant ovarian cancer, missing the coprimary end points of the OVAL trial.

CB-010 Exhibits Impressive Early Efficacy in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

July 20th 2022

OncLive Staff

The CAR T-cell therapy CB-010 displayed promising preliminary efficacy and safety results in patients with relapsed/refractory B-cell non-Hodgkin lymphoma according to findings from the phase 1 ANTLER trial presented during the 2022 Pan Pacific Lymphoma Meeting.

HIMALAYA: Frontline Durvalumab + Tremelimumab in Advanced HCC

July 20th 2022

Tanios Bekaii-Saab, MD

Shared insight on combination durvalumab + tremelimumab as frontline therapy for advanced HCC in the context of data from the HIMALAYA trial.

Overcoming Resistance in HR+/HER2- mBC: Other Novel Targeted Agents

July 20th 2022

Massimo Cristofanilli, MD, FACP

Broad perspectives on various novel mechanisms of action that may address acquired resistance to therapies for HR+/HER2- metastatic breast cancer.

ADCs Begin to Carve a Place in the Treatment Landscape for Ovarian Cancer

July 20th 2022

Brittany Lovely

Patients with recurrent, platinum-resistant ovarian cancer have limited effective treatment options available, but a class of targeted antibody-drug conjugates represent a promising development for this population.

See All News